However, DSF/Cu relieves this feedback activation by ROS-dependently reducing the expression of HER3 and AKT, thereby improving the response of BRAFV600E-mutated thyroid cancer cells to PLX4032. The gene discussed is AKT1; the disease is thyroid cancer.